Chronic kidney disease as a natural model of accelerated cognitive ageing: mechanisms and novel therapeutic directions"

Clicks: 17
ID: 338764
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #227 of 233 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 233 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Cognitive impairment is common in chronic kidney disease (CKD), affecting approximately 40% of patients and increasing sharply as kidney function declines. CKD accelerates many pathophysiological mechanisms shared with brain ageing, with implications for, rather than any equivalence to, the neurodegenerative diseases associated with dementia, notably Alzheimer’s disease and Lewy body dementia. Furthermore, CKD introduces distinct injuries that further amplify these pathways. The convergent mechanisms include cerebral small vessel disease, chronic neuroinflammation, blood-brain barrier (BBB) disruption, accumulation of neurotoxic uraemic solutes, gut-brain-kidney axis dysbiosis, and impaired glymphatic clearance; superimposed on these, haemodialysis imposes repeated episodes of acute cerebral haemodynamic stress. Recent evidence also highlights the kidney’s failure to clear circulating aggregation-prone proteins, such as amyloid-β and α-synuclein. Because these processes develop earlier and progress more rapidly in CKD than in the general ageing population, they effectively create a ‘time-compressed’ version of age-related cognitive decline. In this review, we propose reconceptualising CKD as a prevalent clinical model of accelerated cognitive decline. We examine converging evidence from epidemiology, neuroimaging, and molecular studies to support this hypothesis. Finally, we discuss how emerging therapies—ranging from targeted adsorbents and Klotho replacement to microbiome modulation and preventive immunology—are testable hypotheses in CKD, with possible relevance for dementia in the wider ageing population.
Reference Key
openalex_W7225261727 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag392
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.